Letter of Intent to be submitted by December 17, 2024
CHICAGO , Oct. 30, 2024 /PRNewswire/ — The Metastatic Brain Tumor Collaborative (MBTC), created by the American Brain Tumor Association (ABTA), announces a call for applications for a one-year, $50,000 research grant. Faculty, including junior faculty, are encouraged to apply. Applicants should propose high-risk, high-impact research projects that advance our understanding of brain metastases and have the potential to change current diagnostic or therapeutic paradigms in the treatment of metastatic brain tumors.
The deadline for letters of intent for all interested applicants is December 17, 2024, and researchers can access the application request here.
“When ABTA found there was a lack of patient advocacy organizations dedicated to metastatic brain tumor education and support, we needed to do more to serve this patient population. “We created the Metastatic Brain Tumor Collaborative to bring together like-minded organizations that recognized this,” Nicole said. Wilmarth, ABTA Chief Mission Officer. “This new collaborative research grant will accelerate research and treatment discovery for metastatic brain tumors while understanding how providing critical seed money for promising new research can change lives. This highlights our joint efforts.”
MBTC partners working to support this research opportunity focused on CNS metastases include ABTA, Kidney Cancer Association, LUNGevity Foundation, Melanoma Research Foundation, and Metastatic Breast Cancer Alliance. The larger MBTC (10 organizations in total) aims to support and support patients diagnosed with metastatic brain tumors and to collaboratively advance research that addresses the needs of this patient population.
Metastatic brain tumors start elsewhere in the body and travel to the brain. Lung, breast, kidney, colon, and melanoma (skin cancer) are the most common primary cancers that spread to the brain. Metastatic brain tumors are the most common type of brain tumor in adults. Current estimates suggest that approximately 200,000 adults are diagnosed each year in the United States and that the average prognosis after diagnosis is only a few months.
MBTC is led by national medical experts and offers numerous free educational resources to patients facing a diagnosis of metastatic brain cancer. Additionally, ABTA’s first survey of patients, caregivers and physicians on the diagnosis and treatment of brain metastases, conducted as part of MBTC, revealed disparities in practice patterns and communication regarding metastatic brain tumors. The findings, published in the journal Neuro-Oncology Practice, will increase the accessibility of clinical trials, establish clear treatment standards, and improve physician-patient communication to reflect the unique needs of patients with brain metastases. It highlights the need. This study also highlighted the need for further research into CNS metastases, which provided the impetus to develop a new funding mechanism to specifically fund research to improve care for this patient population. .
MBTC spans a variety of programs for patients and researchers, including Aiming for Melanoma, Go2 for Lung Cancer, Fighting Colorectal Cancer, Kidney Cancer Association, Living Beyond Breast Cancer, LUNGevity Foundation, and Melanoma Research. We are grateful for the unwavering support of our partner organizations. Foundation, Metastatic Breast Cancer Alliance, Neuro-Oncology Society, Susan G. Komen.
About the American Brain Tumor Society
Founded in 1973, the American Brain Tumor Society provides comprehensive resources to support the complex needs of brain tumor patients and their caregivers across all ages and tumor types, as well as breakthroughs in brain tumor diagnosis and treatment. It also provides important funding for research that pursues breakthroughs. , and take care. For more information, visit abta.org or call 800-886-ABTA (2282).
View original content to download multimedia: https://www.prnewswire.com/news-releases/american-brain-tumor-associations-metastatic-brain-tumor-collaborative-announces-50- 000-research-grant-opportunity-to-fund-high-risk-high-impact-cns-metastasis research-302290835.html
Source American Brain Tumor Society
